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Abstract
Background. Postoperative secondary hyperalgesia arises from central sensitization due to pain pathways facilitation and/
or acute opioid exposure. The latter is also known as opioid-induced hyperalgesia (OIH). Remifentanil, a potent l-opioid ago-
nist, reportedly induces postoperative hyperalgesia and increases postoperative pain scores and opioid consumption. The
pathophysiology underlying secondary hyperalgesia involves N-methyl-D-aspartate (NMDA)-mediated pain pathways. In
this study, we investigated whether perioperatively infusing low-dose buprenorphine, an opioid with anti-NMDA activity, in
patients receiving remifentanil infusion prevents postoperative secondary hyperalgesia.
Methods. Sixty-four patients, undergoing remifentanil infusion during general anaesthesia and major lung surgery, were randomly
assigned to receive either buprenorphine i.v. infusion (25lg h1 for 24 h) or morphine (equianalgesic dose) perioperatively. The
presence and extent of punctuate hyperalgesia were assessed one day postoperatively. Secondary outcome variables included post-
operative pain scores, opioid consumption and postoperative neuropathic pain assessed one and three months postoperatively.
Results. A distinct area of hyperalgesia or allodynia around the surgical incision was found in more patients in the control
group than in the treated group. Mean time from extubation to first morphine rescue dose was twice as long in the
buprenorphine-treated group than in the morphine-treated group: 18 vs 9 min (P¼0.002). At 30 min postoperatively, patients
receiving morphine had a higher hazard ratio for the first analgesic rescue dose than those treated with buprenorphine
(P¼0.009). At three months, no differences between groups were noted.
Conclusions. Low-dose buprenorphine infusion prevents the development of secondary hyperalgesia around the surgical
incision but shows no long-term efficacy at three months follow-up.
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Hyperalgesia is clinically defined as an increased pain sensation
following a stimulus that normally provokes pain. Primary
hyperalgesia occurs as a response to a noxious stimulation,
such as trauma or surgical incision, arises from peripheral noci-
ceptor sensitization and is limited to the damaged area.
Secondary hyperalgesia manifests far from the surgically dam-
aged area and is thought to be due to central sensitization.
Opioid-induced hyperalgesia (OIH), namely nociceptive sensiti-
zation induced by exposure to opioids, is part of secondary
hyperalgesia.1–3 OIH follows opioid analgesia and may last long
after withdrawal.2
Among the various l-opioid agonists, remifentanil is a
potent and ultra-short-acting opioid widely used during general
anaesthesia. On withdrawal, even after short-term infusion,
remifentanil may induce hyperalgesia in the area surrounding
the surgical site4 and increase postoperative opioid consump-
tion.4–6 Experimental studies have also described remifentanil-
induced hyperalgesia in healthy subjects.7
Although the mechanisms underlying secondary hyperalgesia
and OIH remain unclear, some attribute a key role to N-methyl-
D-aspartate (NMDA)-related pain facilitation.8 9 Experimental and
clinical studies in animals and humans have shown that NMDA-
receptor antagonists prevent the development of secondary
hyperalgesia and OIH.2 4 10 11 Like ketamine,11 12 another NMDA
receptor antagonist frequently used in experimental studies,
buprenorphine also seems to counteract remifentanil-induced
hyperalgesia at small doses (0.15 mg i.v.).13 Possible explanations
for buprenorphine anti-hyperalgesia include its k-receptor antag-
onism that may block pro-nociceptive NMDA-mediated activity
through a dynorphin-mediated mechanism,13 14 altered spinal
dynorphine levels,15 downregulation of d-receptors16 and
enhanced descending facilitation.14 Buprenorphine abolishes
remifentanil-induced post-infusional hyperalgesia in healthy vol-
unteers undergoing transcutaneous electrical stimulation.13 It
also has a broad analgesic profile and offers the opportunity to
treat different pain phenotypes, including neuropathic pain
symptoms.17 No data yet show whether buprenorphine infused
continuously at a low dose could prevent secondary hyperalgesia
and OIH after surgical procedures, especially after those with an
increased risk of developing chronic pain postoperatively such as
major lung surgery.18 This information would help in preventing
postoperative hyperalgesia and/or allodynia, thus reducing the
patient’s acute postoperative discomfort and possibly reducing
the risk of postoperative chronic pain. Thoracotomy is considered
one of the surgical procedures at the highest risk of postoperative
persistent pain (>3 months). The incidence of moderate/severe
thoracic pain at 1 yr following thoracotomy is between 11–30%
and 3–5%, respectively.18–20 Usually, in most patients, post-
thoracotomic pain is severe until 1 month postoperatively, then
gradually decreases at 1 yr postoperatively.19
In this double-blind, randomized, active-control trial, we
investigated whether low-dose buprenorphine infusion
prevents or reduces secondary hyperalgesia after major lung
surgery. To do so, before inducing general anaesthesia in
patients undergoing thoracotomy, we started a low-dose
buprenorphine i.v. infusion and assessed, as primary end-
points, the presence and extension of postoperative punctu-
ate hyperalgesia measured by quantitative sensory testing
(QST). As secondary outcomes, we collected postoperative
pain scores, opioid consumption and postoperative neuro-
pathic pain at one and three months after surgery. Control
patients underwent the same general anaesthesia but
instead of buprenorphine received an equianalgesic morphine
infusion.
Methods
Patient selection and study design
This single-centre, double-blind, prospective, randomized,
active-control trial was conducted after local Institutional
Review Board approval and in accordance with good clinical
practice and the guidelines set out in the Declaration of
Helsinki. Informed consent was obtained from each patient.
Eligible patients undergoing major lung surgery under the same,
experienced surgeon were consecutively included in this trial
from the Department of Thoracic Surgery at our university
teaching hospital. The trial was registered on Current
Controlled Trial (http://www.controlled-trials.com/) with num-
ber ISRCTN91017061.
Eligible patients met the following inclusion criteria: age
18 yr or older; ASA class I–III; planned, open, unilateral lung sur-
gery by lateral thoracotomy; and the express refusal to undergo
intraoperative or postoperative thoracic epidural analgesia.
Exclusion criteria included: extremely high or low weight (less
than 40 kg and greater than 100 kg); known opioid drug abuse;
ongoing chronic opioids and/or antidepressant and/or anticon-
vulsive treatment; inability to manage a patient-controlled
analgesia (PCA) device; moderate-to-severe pre-existing chronic
obstructive pulmonary disease [forced expiratory volume in 1 s
(FEV1) <50% predicted]; chronic renal insufficiency; diabetes; or
peripheral neuropathy.
During preoperative assessment, all patients that were
enrolled were informed about the study objectives and protocol,
and were shown how to use a visual analogue scale (VAS), a
PCA device and received a demonstration of QST. Patients were
randomly allocated using an online research randomizer
(https://www.randomizer.org) into two groups (32 patients
each) to receive intraoperative and postoperative continuous
infusion of low-dose buprenorphine (25 lg h–1, TemgesicVR ,
Schering-Plough SpA, Italy) or an equianalgesic, control infusion
of morphine (834 lg h–1, morphine chlorhydrate, Molteni
Farmaceutici, Italy; 0.3 mg of i.v. buprenorphine was considered
equianalgesic to 10 mg of i.v. morphine).21 Each drug infusion
was prepared in an elastomeric infusor (Infusor SV2 System,
flow rate: 2 ml h–1; Baxter International Inc., Deerfield, Illinois,
USA) by a nurse blinded to the study protocol, and both drugs
were diluted in NaCl 0.9% up to a final buprenorphine concen-
tration of 12.5 lg ml–1 and a morphine concentration of 417 lg
ml–1. Drug infusion was started at anaesthesia induction and
discontinued 24 h later. The infusion was not labelled.
Editor’s key points
• Opioid-induced hyperalgesia (OIH: paradoxical increase in
pain from opioids) may be problematic postoperatively.
• Buprenorphine may reduce OIH due to central, non-
opioid receptor effects.
• Hyperalgesia after perioperative buprenorphine was
compared to morphine after thoracic surgery.
• Buprenorphine resulted in less postoperative hyperalge-
sia than morphine
• Further studies are needed to improve diagnosis and
management of acute OIH.
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Nurses in charge of postoperative care and staff members
who collected the data were blinded to the study protocol and
randomization.
General anaesthesia and postoperative analgesia
Anaesthetic management was standardized for all study
patients. All patients received the same i.v. premedication 1 h
before surgery (midazolam 0.02 mg kg1, ketorolac 15 mg, para-
cetamol 1 g) and the same remifentanil-based general anaesthe-
sia, supplemented with oxygen and desflurane. A commercial
target-controlled infusion (TCI) pump (Alaris PK Syringe Pump,
Cardinal Health, Rolle, Switzerland) was used to control the
effect-site TCI of remifentanil according to a pharmacokinetics
model.22 In both groups, in patients breathing oxygen, anaes-
thesia was induced with propofol (2–2.5 mg kg1) and a remifen-
tanil TCI to obtain a predicted site-effect concentration of 5 ng
ml1. Tracheal intubation with a double lumen tube was facili-
tated with cis-atracurium (0.15 mg kg1). Anaesthesia was then
maintained with desflurane, oxygen mixed with air and remi-
fentanil TCI of 4 ng ml1. Continuous ECG, invasive arterial
blood pressure, plethysmographic oxygen saturation, end-tidal
carbon dioxide and desflurane concentrations were monitored
using an S/5 anaesthesia monitor (GE Datex-Ohmeda, Helsinki,
Finland). Approximately 30 min before surgery ended, all
patients received an i.v. bolus of morphine (150 lg kg1). Once
extubated, patients were transferred to the post-anaesthesia
care unit (PACU) for 2 h where a nurse blinded to the study pro-
tocol administered i.v. morphine titrated to reach a VAS score
3 (3 mg of morphine every 5 min), before connecting each
patient to a PCA device (Gemstar, Abbott, North Chicago, IL,
USA) containing morphine 0.5 mg ml–1 (bolus dose, 1 mg; lock-
out time, 7 min; maximum dose allowed in 4 h, 20 mg). Pre-PCA
opioid consumption was assessed by measuring time from
extubation to first morphine rescue dose (in the first 30 postop-
erative minutes) and total morphine titration dose required to
reach a VAS score 3. In addition to PCA, according to a multi-
modal postoperative analgesic regimen routinely used at our
institution, each patient received 1 g of paracetamol every 6 h
and 30 g of ketorolac every 8 h during the first postoperative
day. After surgery ended, as secondary outcomes, a nurse
blinded to the study protocol and randomization collected VAS
scores at rest and during coughing at 8, 16, 24 and 48 h, total
morphine PCA consumption, blood–gas analysis values, and the
incidence of postoperative nausea and vomiting (PONV) at 24 h.
QST
QST took place in a quiet room kept at a constant temperature
(22 C). On the day before surgery, the same investigator tested
all of the patients to assess pain and tactile thresholds at the
site of the probable surgical incision (between the T5 and T6 ribs
along the mid-axillary line) and at the corresponding area on
the contralateral side. On the day after surgery, each patient
was evaluated to determine four QST variables: changes in
static mechanical pain perception threshold on the operated
side (1 cm away from and around the surgical incision) and on
the contralateral side, and the existence and size of hyperalge-
sic and allodynic areas around the surgical incision. The con-
tralateral side was always probed first, both before and after
surgery.
The tactile threshold for punctuate mechanical stimuli was
assessed using 20 calibrated (0.008–300 g mm2) von Frey fila-
ments (NC-17775 Von FreyVR Filaments, Bioseb, Chaville, France).
The von Frey filaments were applied in ascending order of stiff-
ness, with approximately 10 s elapsing between two successive
stimuli, to avoid temporal summation.23 The tactile threshold
was defined as the smallest force (g mm2) necessary to bend a
von Frey hair, and perceived by the patient as three consecutive
skin touches. If the tactile pain threshold exceeded hair number
6.65 (300 g mm2), skin sensitivity was censored at that number.
The pain threshold for punctuate mechanical stimuli was
assessed with the same set of von Frey filaments and the same
procedures, and defined as the smallest force necessary to bend
a filament, and perceived by the patient as three consecutive
painful stimuli.
The hyperalgesic area around the surgical incision was
measured by modifying a previously described method.24–26
Each patient was tested with the von Frey filament that in post-
operative pain threshold testing evoked pain on the opposite
side. Stimulation was started far from the surgical incision and
moved toward the incision in 1 cm steps until the patient
reported a distinct change in pain perception. The first point at
which the patient reported a more painful, sore or sharp feeling
was marked, and the distance to the incision was measured
(Fig. 6). Finally, we calculated the incidence and extension of
peri-incisional mechanical hyperalgesia (defined as the pres-
ence of hyperalgesia, regardless of its degree).
To test the allodynic area around the surgical incision, each
patient was assessed with the von Frey filament just below the
one that evoked pain on the opposite side in the postoperative
pain threshold test. Stimulation started far away from the surgi-
cal incision and moved towards the incision at 1 cm steps until
the patient reported a distinct change in perception, from a
touch sensation to a painful, sore or sharp feeling was marked,
and the distance to the incision measured. The incidence and
extension of the allodynic area were then calculated as
described for the hyperalgesia area.
Pain evaluation at one and three months
Patients were contacted by telephone at one and three months
after hospital discharge to collect data about postoperative pain.
Patients measured pain intensity at one and three months using
the numeric rating scale (NRS). A cut-off value of NRS >50 was
then applied to identify severe and disabling pain as previously
suggested.18 To distinguish between non-neuropathic and neu-
ropathic components of postoperative pain reported at one and
three months, we used the PainDETECT Questionnaire (PD-Q), a
validated, easy to use, patient-based (self-report) screening tool
that quantifies to what extent neuropathic components contrib-
ute to chronic pain.27 28 The PD-Q incorporates seven weighted
sensory descriptor items (never to very strongly) and two items
relating to the spatial (radiating) and temporal characteristics of
the individual pain pattern: none of the items requires a clinical
examination. The German PD-Q was translated into Italian by a
professional translator; all of the patients received two copies of
the questionnaire on hospital discharge.
Statistical analysis
Data were analysed using SPSS 15.0 package (SPSS Inc., Chicago,
IL, USA). Results for normally distributed data for quantitative
variables were expressed as mean [95% confidence interval (CI)]
or median (inter-quartile range), and for qualitative variables as
percentage. Student’s t-test or Mann–Whitney U-test were used
to assess differences for quantitative variables, and Pearson’s v2
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test or Fisher’s exact test were used to assess differences for
qualitative variables.
Because the threshold values for the outcome variables
assessed follow an exponential pattern, values for further anal-
ysis were log transformed. Preoperative collected data were con-
sidered as reference and used to normalize postoperative test
results for individual patients by calculating the z-transform:
z-score¼ (single value for each patient minus mean value for
controls) divided by the standard deviation (SD) of controls.29
The time required for the first requested morphine rescue
dose in the PACU in the first 30 postoperative minutes was eval-
uated by survival analysis (survival was equivalent to ‘no mor-
phine request’). Kaplan–Meier survival curves were constructed
and the null hypothesis of no difference in survival among
groups was tested with the log-rank test. The Cox proportional
hazards model was used to calculate the hazard ratio with its
relative 95% CI.
A P-value <0.05 was considered to indicate statistical
significance.
Primary end-points were the presence and extent of the
hyperalgesic area. From a pilot study conducted in the same set-
ting, we hypothesized that patients treated with buprenorphine
would have a 50% risk of a postoperative hyperalgesic area
developing around the surgical incision (vs almost all of the
patients receiving the control infusion). If hyperalgesia devel-
oped, we also hypothesized a 35% reduction in its extent vs con-
trols (an expected difference in populations means of 26 cm2
with an expected SD of 36 cm2). A sample of 30 subjects
per group would be sufficient to reject the null hypothesis that
a hyperalgesic area would develop in a similar number of sub-
jects in both groups, and have a similar mean extent, with 0.8
probability (power), and a 5% risk of type I error.30 To account
for possible dropouts, we planned to enrol 32 patients in each
group.
Results
Patient characteristics
Of the 64 patients prospectively enrolled for this trial, 63 suc-
cessfully completed the study (31 in the buprenorphine group
and 32 in the control group); data for one patient were excluded
from the analysis for technical reasons linked to poor nocturnal
PCA management. Demographic characteristics of the studied
population are shown in Table 1. No differences were found in
the preoperative variables between groups or in the length of
Assessed for eligibility (n=64)
Randomized (n=64)
Excluded (n=0)
Not meeting inclusion criteria (n=0)
Declined to participate (n=0)
Enrolment
Allocation
Analysis
Allocated to i.v. buprenorphine (n=32) Allocated to i.v. morphine (n=32)
Analysed (n=32)
Received allocated intervention (n=32)
Analysed (n=31)
Received allocated intervention (n=32)
Excluded from analysis for technical reasons
(n=1)
Fig 1 Flow diagram of the progress through the phases of trial.
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hospital stay, and no postoperative complications of impor-
tance developed during the three month follow-up.
Postoperative analgesia
Mean time from extubation to first morphine rescue dose was
twice as long in the group treated with buprenorphine than in
patients receiving morphine (Fig. 2): 18 min (95% CI 14–23) vs
9 min (95% CI 6–12) (P¼0.002 by log-rank test). Thirty minutes
after surgery ended, the risk of receiving an analgesic rescue
dose was higher in patients receiving morphine than in those
receiving buprenorphine: hazard ratio 2.67 (1.27–5.64) (P¼0.009
by Cox proportional hazard model). No significant difference
was found in the total morphine titration dose required to dis-
charge patients from the PACU between the two treated groups
(P¼0.08).
Although no difference was found in morphine PCA con-
sumption between groups, buprenorphine induced a signifi-
cantly larger reduction in postoperative VAS pain scores, both at
rest and during coughing and at all time points, in the treated
group than in the control group (P<0.05, Fig. 5).
Postoperative QST
Buprenorphine treatment significantly increased postoperative
tactile and pain thresholds at 1 cm from the surgical incision
(Table 2, Fig. 4). After buprenorphine infusion, but not after mor-
phine infusion, postoperative tactile thresholds increased more
on the operated side than on the contralateral side.
QST disclosed a distinct area of hyperalgesia around the sur-
gical incision in more patients in the control group than in the
treated group (87 vs 27%). The mean hyperalgesic area was sig-
nificantly smaller in patients treated with low-dose buprenor-
phine infusion than in controls receiving morphine alone
(Fig. 3). No difference was found in the extent of allodynic areas
(Table 2). Of note, a small number of patients complained of
allodynia in both groups without statistical significance.
Pain evaluation
The response rate to the postoperative telephone interviews
was 60% at one month and 73% at three months. One month
after surgery, fewer patients in the buprenorphine group than in
the morphine group reported having severe, disabling pain (NRS
>5) (16.7 vs 50%). At three months, the difference between
groups disappeared (buprenorphine, 13.6%; morphine, 27.3%).
No significant differences were found between groups in PD-Q
scores or in the percentage of patients with a high or low proba-
bility of neuropathic pain (Table 2).
Discussion
In this double-blind, randomized, active-controlled trial, we pro-
vide new evidence showing that buprenorphine, infused at a
low dose during general anaesthesia in patients undergoing
major lung surgery, prevents peri-incisional postoperative
hyperalgesia and reduces the hyperalgesic area. The risk of
hyperalgesia developing was significantly lower in
buprenorphine-treated patients than in the untreated controls
(27 vs 87%).
Because surgically-induced primary and secondary hyperal-
gesia cannot be clinically distinguished from OIH, it is difficult
to speculate on which of the two our patients’ QST scores
reflect. Although remifentanil is widely used owing to its rapid
and predictable onset and offset, many studies describe hyper-
algesic effects after remifentanil infusion even in healthy volun-
teers.11 12 31 32 In patients undergoing remifentanil infusion,
who often report receiving unsatisfactory analgesia, some
investigators also describe acute drug tolerance and underline
the need for greater postoperative analgesic doses.5 It is difficult
to discern, in clinical settings, to what extent either hyperalge-
sia or acute tolerance contribute to patients’ reported pain and
opioid consumption, thus we conjecture that in our patients
and controls both these unwanted effects developed. Although
the mechanisms underlying hyperalgesia and acute tolerance
are still unknown, literature reports central nociceptive system
activation through NMDA receptors.33 Zhao and colleagues8
have also shown that remifentanil induces an increased NMDA-
mediated response through activation of r receptors. Activation
of m and r receptors, but not k, has been implicated as one of the
mechanisms underlying development of OIH.34 Activation of l
receptors by morphine increases cellular expression of r recep-
tors.35 Moreover pharmacological inhibition and genetic mitiga-
tion of r receptors increase l-mediated spinal anti-nociceptive
effects and inhibit tolerance in animals treated with mor-
phine.35 In an experimental study, Ddrla and colleagues36
showed that opioid-induced hyperalgesia, namely opioid-
withdrawal-related long-term potentiation at first C-fibre syn-
apses, can be prevented by an NMDA-receptor antagonist
Table 1 Demographic characteristics. Unless specified, all values are expressed as mean (95% CI). Type of surgery: 1, lobectomy; 2, sleeve
resection; 3, atypical resection; 4, pneumectomy
Groups
Variables Buprenorphine (n¼31) Morphine (n¼32) P-value between groups
Age (yr) 66 (63–69) 63 (60–66) 0.21
Height (cm) 167 (164–170) 166 (163–168) 0.74
Weight (kg) 70 (66–75) 72 (67–77) 0.63
Gender (% male) 55 53 0.89
ASA class I/II/III (n) 3/18/10 3/24/5 0.14
Type of surgery 1/2/3/4 (n) 18/3/10/0 14/2/14/2 0.34
Surgical incision (cm) 12 (11–14) 11 (10–12) 0.12
Duration of surgery (min) 108 (90–127) 109 (92–125) 0.97
Hospital stay (day) 7 (6–8) 7 (6–8) 0.64
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without affecting acute synaptic opioid agonist depression.
Convincing clinical and experimental evidence confirms that
NMDA receptors have a key role in inducing and maintaining
hyperalgesia.11 12 32 37
Postoperative hyperalgesia developed in both of our study
groups; however, fewer patients complained of hyperalgesia,
and the extent of the hyperalgesic area was significantly smaller
in patients treated with buprenorphine (an opioid with NMDA-
mediated anti-hyperalgesic properties) than in controls
(Fig. 3).38 No differences between groups were found in the
dimension of allodynic areas (Table 2).
We cannot differentiate to what extent buprenorphine coun-
teracted post-remifentanil OIH instead of surgically-induced
hyperalgesia; it is possible that buprenorphine, through its anti-
NMDA action, could have reduced both. In experimental models
of acute and chronic pain in rats, buprenorphine significantly
inhibits the development of mechanic and thermal allodynia and
mechanic hyperalgesia.17 Also, in experimental human models,
buprenorphine significantly decreases hyperalgesic areas, and its
anti-hyperalgesic effects seem to be more pronounced and last
longer than those induced by other conventional analgesics.13
A possible explanation for the buprenorphine anti-hyperalgesiac
effect is its k-receptor antagonism which, through a dynorphin-
mediated mechanism, may block pro-nociceptive NMDA-medi-
ated activity.13 14
The reason why we measured hyperalgesic and allodynic
areas with QST,39 before and after surgery, and on the con-
tralateral non-operated side, is that neither postoperative VAS
nor opioid consumption correlate with the development of
hyperalgesia. We measured the hyperalgesic area around the
surgical incision by modifying a previously described
method.24–26 Our QST experimental protocol aimed to provide
variables for assessing sensory loss (hypoesthesia) and sen-
sory gain (hyperalgesia, allodynia, hyperpathia). Detailed
sensory examinations can identify the mechanisms underly-
ing postoperative pain processing. Contrasting results have
been reported for the tactile threshold, increased or decreased,
in the area around the wound or inflammation.40 41 A strength
of our study is that by comparing preoperative and postopera-
tive tactile and painful thresholds we established the normal
thresholds for each subject and measured possible changes.
Because ‘hyperalgesic’ areas measured with a punctuate probe
should be technically considered as areas of allodynia rather
than of hyperalgesia,39 each patient was tested with the von
Frey filament that evoked pain in the postoperative test
for pain threshold on the opposite side. According to the
International Association for the Study of Pain (IASP) defini-
tions of hyperalgesia and allodynia, whether stimuli are nor-
mally painful or normally non-painful determines the
difference between them. In buprenorphine-treated patients,
QST showed significantly increased tactile and pain thresh-
olds. The statistical z-value compares tactile and pain thresh-
olds for each patient with those for controls. Values close to 0
indicate no difference with controls, significantly positive val-
ues indicate the thresholds are higher than those in controls
(gain of function), whereas significantly negative values signal
loss of function (Fig. 4). When we assessed the tactile and pain
thresholds on the contralateral non-operated side, we found
them higher than those in controls. This finding suggests that
buprenorphine probably induces its anti-hyperalgesic action
through a central mechanism: on the operated side, buprenor-
phine increased pain thresholds and reduced hyperalgesia; on
the contralateral non-operated side, buprenorphine increased
tactile thresholds. The combined sensory loss, pain and low-
ered pain detection thresholds to different stimuli is a pheno-
type characteristic for neuropathic pain.40
Thoracotomy is, along with limb amputation, considered to
be the surgical procedure that elicits the highest risk of severe
Table 2 Postoperative analgesia, quantitative sensory testing (QST), and one and three month pain evaluation in the two groups. If not
specified, all values are expressed as mean (95% CI). All P-values have been approximated to the second decimal. PACU, post-anaesthesia
care unit; PCA, patient-controlled analgesia; PONV, postoperative nausea and vomiting; PD-Q, PainDETECT Questionnaire; NRS, numeric
rating scale. A PD-Q score <18 indicates that a neuropathic pain component could be present
Group
Variables Buprenorphine (n¼31) Morphine (n¼32) P-value between groups
Postoperative analgesia
Morphine titration in the PACU (mg) 17 (12–21) 13 (10–17) 0.26
Total morphine PCA consumption (mg) 7 (4–10) 11 (8–14) 0.08
Time from extubation to first morphine (min) 18 (14–23) 9 (6–12) 0.01
PONV (%) 9.7 21.9 0.31
Postoperative QST
z-values for tactile threshold changes 1.04 (0.57–1.50) 0.15 (0.56–0.86) 0.04
z-values for pain threshold changes 0.53 (0.10–0.96) 0.11 (0.60–0.37) 0.04
Presence of area of hyperalgesia (%) 27 87 0.01
Extent of area of hyperalgesia (cm2) 40 (21–59) 74 (59–88) 0.02
Extent of area of allodynia (cm2) 49 (35–63) 71 (46–97) 0.32
One and three months pain evaluation
PD-Q score at 1 month 7 (4–10) 10 (7–13) 0.15
PD-Q score at 3 months 7 (5–10) 8 (6–11) 0.60
PD-Q score <18 at 1 month (%) 17 33 0.44
PD-Q score <18 at 3 month (%) 9 32 0.13
Patients with severe pain (NRS >5) at 1 month (%) 16 50 0.05
Patients with severe pain (NRS >5) at 3 months (%) 14 27 0.46
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chronic postoperative pain,18 half of which definitely or possibly
includes a neuropathic component.28 Although we could not
detect hypoesthesia owing to persistent primary and secondary
hyperalgesia around the surgical site, buprenorphine’s anti-
hyperalgesic action may explain why we found increased tactile
and pain thresholds in the treated patients. Why buprenorphine
infusion significantly increased the tactile threshold on the
operated side compared with the contralateral side whereas
morphine infusion did not, remains unclear.
In a recent exhaustive review on postoperative OIH, Fletcher
and Martinez6 reported a 24 h increase in postoperative pain, a
moderate increase in morphine use, with no impact on opioid-
related side effects, attributed to remifentamil-induced hyperal-
gesia. In our study, we showed that, although the total mor-
phine titration dose required to discharge patients from the
PACU did not significantly differ between treated groups,
patients treated with buprenorphine had reduced postoperative
pain scores, both at rest and during coughing, during their PACU
stay (Fig. 5). We also found that the time elapsing between extu-
bation and the first morphine rescue dose was twice as long in
buprenorphine-treated patients than in the controls (Fig. 2).
Although the patients treated with buprenorphine experi-
enced markedly less severe pain than controls one month post-
operatively, this difference disappeared at three months. This
result suggests that buprenorphine counteracts persistent post-
operative pain, leaving the risk of developing chronic pain
unchanged; definitive conclusions await a larger study with the
same setting and methodology.
Our study has several limitations. First, being beyond the scope
of our study, we decided not to analyse all possible QST variables
(pressure, thermal and vibration thresholds) to reduce the dura-
tion (and potential discomfort) of the testing phase. Although the
QST results in our study almost match the reference values pub-
lished by the German Research Network on Neuropathic Pain,29
we cannot compare the two directly because, at the time of analy-
sis, they examined the hip rather than the chest, the studied pop-
ulation was younger and their testing algorithm differed from
ours. Second, our modified protocol to measure postoperative
hyperalgesia has some limits worth mentioning, namely the
choice of von Frey filaments as testing probes and the potential
bias of intra-subject side differences in the threshold value
measurements. Thick von Frey filaments not only stimulate
0.8 1.0 1.2 1.4
Buprenorphine–preoperative threshold
1.6
0.8 1.0 1.2 1.4
Morphine–preoperative threshold Morphine–postoperative threshold
1.6 0.8 1.0 1.2 1.4 1.6
0.8 1.0
Tactile thresholds
1.2 1.4
Buprenorphine–postoperative threshold
1.6
Fig 4 Bar histograms showing increased postoperative tactile threshold 1 cm from the surgical incision in the buprenorphine group with respect to control.
Normalized and log-transformed values for tactile thresholds (x-axis); number of patients (y-axis).
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low-threshold Ab fibres, but also Ad-fibre nociceptors (because the
filament has sharp edges) or even C-fibre nociceptors (usually in
patients with peripheral sensitization).42 Because currently avail-
able bedside techniques cannot stimulate Ab, Ad or C-fibre affer-
ents selectively,39 experiments using von Frey filaments to
quantify punctuate hyperalgesia cannot determine to what extent
these different pathophysiology mechanisms are involved. Also,
we did not take into account any potential threshold differences
between the surgical and contralateral sides during the postopera-
tive testing session, and we have always used the contralateral
side to define ‘normal’ threshold values. The German PD-Q ques-
tionnaire, although professionally translated into Italian, it was
not yet validated in Italy at time of administration, so its ability to
discriminate a neuropathic pain component in a population of
Italian subjects was still unknown. Last, the multimodal analgesic
regimen might have interfered with acute opioid tolerance.31
In conclusion, a perioperative low-dose infusion of bupre-
norphine given to patients undergoing major thoracic surgery
under remifentanil infusion is effective in preventing or reduc-
ing postoperative hyperalgesia. The drug reduces postoperative
pain in the acute setting but it is not effective in preventing
development of chronic postoperative pain.
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